<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04647214</url>
  </required_header>
  <id_info>
    <org_study_id>MED-MA-EYE-0648</org_study_id>
    <nct_id>NCT04647214</nct_id>
  </id_info>
  <brief_title>18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)</brief_title>
  <acronym>ARGOS</acronym>
  <official_title>ARGOS - A Phase IV, Prospective, 18-month Study to Assess the Effectiveness and Safety of Bimatoprost Intracameral Implant (DURYSTA) in US Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to collect effectiveness and safety data after administration of a bimatoprost&#xD;
      intracameral implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of treated eyes that did not receive additional Intraocular Pressure (IOP) -lowering intervention/therapy per standard medical care</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated eyes not receiving additional IOP-lowering intervention/therapy per standard medical care</measure>
    <time_frame>Baseline to Month 4</time_frame>
    <description>IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated eyes not receiving additional IOP-lowering intervention/therapy per standard medical care</measure>
    <time_frame>Baseline to Month 9</time_frame>
    <description>IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated eyes not receiving additional IOP-lowering intervention/therapy per standard medical care</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated eyes not receiving additional IOP-lowering intervention/therapy per standard medical care</measure>
    <time_frame>Baseline to Month 18</time_frame>
    <description>IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from bimatoprost intracameral implant to first additional IOP-lowering intervention/therapy</measure>
    <time_frame>Baseline to Month 18</time_frame>
    <description>Time to first IOP-lowering intervention is defined as the time between treatment and IOP-lowering intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated eyes achieving the predefined IOP outcomes without receiving additional IOP-lowering intervention/therapy</measure>
    <time_frame>Baseline to Month 4</time_frame>
    <description>IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated eyes achieving the predefined IOP outcomes without receiving additional IOP-lowering intervention/therapy</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated eyes achieving the predefined IOP outcomes without receiving additional IOP-lowering intervention/therapy</measure>
    <time_frame>Baseline to Month 9</time_frame>
    <description>IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated eyes achieving the predefined IOP outcomes without receiving additional IOP-lowering intervention/therapy</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated eyes achieving predefined IOP outcomes without receiving additional IOP-lowering intervention/therapy</measure>
    <time_frame>Baseline to Month 18</time_frame>
    <description>IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean reduction in the number of topical IOP-lowering medications</measure>
    <time_frame>Baseline to Month 4</time_frame>
    <description>A numerical count by class of drug of topical IOP lowering medications being taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean reduction in the number of topical IOP-lowering medications</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>A numerical count by class of drug of topical IOP lowering medications being taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean reduction in the number of topical IOP-lowering medications</measure>
    <time_frame>Baseline to Month 9</time_frame>
    <description>A numerical count by class of drug of topical IOP lowering medications being taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean reduction in the number of topical IOP-lowering medications</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>A numerical count by class of drug of topical IOP lowering medications being taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean reduction in the number of topical IOP-lowering medications</measure>
    <time_frame>Baseline to Month 18</time_frame>
    <description>A numerical count by class of drug of topical IOP lowering medications being taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated eyes achieving complete success</measure>
    <time_frame>Baseline to Month 4</time_frame>
    <description>Complete success is defined as treated eyes with IOP &lt;=18 mm Hg without any additional IOP lowering interventions/therapies after administration of the bimatoprost intracameral implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated eyes achieving complete success</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Complete success is defined as treated eyes with IOP &lt;=18 mm Hg without any additional IOP lowering interventions/therapies after administration of the bimatoprost intracameral implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated eyes achieving complete success</measure>
    <time_frame>Baseline to Month 9</time_frame>
    <description>Complete success is defined as treated eyes with IOP &lt;=18 mm Hg without any additional IOP lowering interventions/therapies after administration of the bimatoprost intracameral implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated eyes achieving complete success</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Complete success is defined as treated eyes with IOP &lt;=18 mm Hg without any additional IOP lowering interventions/therapies after administration of the bimatoprost intracameral implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated eyes achieving complete success</measure>
    <time_frame>Baseline to Month 18</time_frame>
    <description>Complete success is defined as treated eyes with IOP &lt;=18 mm Hg without any additional IOP lowering interventions/therapies after administration of the bimatoprost intracameral implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated eyes achieving qualified success</measure>
    <time_frame>Baseline to Month 4</time_frame>
    <description>Partial success is defined as treated eyes with IOP &lt;=18 mm Hg with no Secondary Surgical Intervention (SSI) for glaucoma, while staying on the same or fewer topical IOP-lowering medications than baseline and or Selective Laser Trabeculoplasty (SLT), Argon Laser Trabeculoplasty (ALT) or MicroPulse Laser Trabeculoplasty (MLT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated eyes achieving qualified success</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Partial success is defined as treated eyes with IOP &lt;=18 mm Hg with no Secondary Surgical Intervention (SSI) for glaucoma, while staying on the same or fewer topical IOP-lowering medications than baseline and or Selective Laser Trabeculoplasty (SLT), Argon Laser Trabeculoplasty (ALT) or MicroPulse Laser Trabeculoplasty (MLT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated eyes achieving qualified success</measure>
    <time_frame>Baseline to Month 9</time_frame>
    <description>Partial success is defined as treated eyes with IOP &lt;=18 mm Hg with no Secondary Surgical Intervention (SSI) for glaucoma, while staying on the same or fewer topical IOP-lowering medications than baseline and or Selective Laser Trabeculoplasty (SLT), Argon Laser Trabeculoplasty (ALT) or MicroPulse Laser Trabeculoplasty (MLT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated eyes achieving qualified success</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Partial success is defined as treated eyes with IOP &lt;=18 mm Hg with no Secondary Surgical Intervention (SSI) for glaucoma, while staying on the same or fewer topical IOP-lowering medications than baseline and or Selective Laser Trabeculoplasty (SLT), Argon Laser Trabeculoplasty (ALT) or MicroPulse Laser Trabeculoplasty (MLT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated eyes achieving qualified success</measure>
    <time_frame>Baseline to Month 18</time_frame>
    <description>Partial success is defined as treated eyes with IOP ≤18 mm Hg with no Secondary Surgical Intervention (SSI) for glaucoma, while staying on the same or fewer topical IOP-lowering medications than baseline and or Selective Laser Trabeculoplasty (SLT), Argon Laser Trabeculoplasty (ALT) or MicroPulse Laser Trabeculoplasty (MLT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing treatment emergent adverse events</measure>
    <time_frame>Baseline to Month 18</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Open-angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Bimatoprost intracameral implant (DURYSTA) 10μg</arm_group_label>
    <description>Patients with OAG or OHT who are scheduled for intracameral administration of a bimatoprost intracameral implant by their ophthalmologist.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include US patients with OAG or OHT who are scheduled for&#xD;
        administration of a bimatoprost intracameral implant by their ophthalmologist.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patient diagnosed with OAG or OHT who is scheduled to receive a bimatoprost intracameral&#xD;
        implant in at least one eye.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - A history of any of the following ocular surgeries in the eye due to receive a&#xD;
        bimatoprost intracameral implant:Ahmed Glaucoma Valve, Baerveldt shunt, Ex-Press glaucoma&#xD;
        shunt implantation, Molteno shunt, Trabeculectomy, Vitrectomy, retinal surgery, CyPass&#xD;
        Micro-Stent or Anterior Chamber Intraocular Lens (AC IOL) placement.&#xD;
&#xD;
          -  Concurrent or anticipated enrollment in an interventional clinical trial involving&#xD;
             either an investigational medicinal product or medical device.&#xD;
&#xD;
          -  Previous enrollment in another Allergan bimatoprost intracameral implant study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Angeles Eye Institute /ID# 240368</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hamilton Glaucoma Center Shiley Eye Center UCSD /ID# 240364</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Bay Eye Associates Inc. /ID# 240362</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954-2387</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colorado Eye Institute /ID# 240798</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80924-7003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MedEye Associates /ID# 240374</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgia Eye Partners /ID# 240061</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stiles Eyecare Excellence /ID# 240376</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Eye Care Institute /ID# 240367</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hudson Eye /ID# 240805</name>
      <address>
        <city>Jersey City</city>
        <state>New Jersey</state>
        <zip>07306-2929</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bergstrom Eye Research LLC /ID# 240363</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>META Medical Research Institute, LLC /ID# 240800</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45432-1400</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oklahoma Eye Surgeons /ID# 240373</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>El Paso Eye Surgeons, P.A. /ID# 240366</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Eye Centers of Racine and Kenosha LTD /ID# 240059</name>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <zip>53405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2020</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

